Phase 2/3 trials of Bharat Biotech International Limited’s nasal vaccine against the coronavirus disease (Covid-19) are likely to begin “within a couple of weeks” at the All India Institute of Medical Sciences (AIIMS) in Delhi, according to news agency ANI. The Hyderabad-based company received regulatory approvals to conduct the second and third phase trials of the intranasal vaccine, BBV154, in August.
An epidemiological study was conducted by AIIMS, Delhi which has now revealed that the positivity rate of SARS COVID was high in children and was comparable to the positivity rate in adults. The serosurvey also reveals and suggest that it is unlikely that any future third wave by prevailing COVID-19 variant would disproportionately affect children who are above the age of 2.
Drug firm Venus Remedies on Thursday said it has won a 10-year-long patent battle against French firm SCR Pharmatop with regards to production of the intravenous paracetamol solution in the country.
The AIIMS in New Delhi has decided to resume routine inpatient admissions and elective surgeries at its general and private wards and in all its centres with immediate effect, according to an order by the hospital administration.
AIIMS Delhi has started screening children for trial of Bharat Biotech's coronavirus vaccine on those aged between 2 aand 18 on Monday. Similar trials have already begun at AIIMS Patna to see if Covaxin is suitable for children. The vaccine is currently only being administered on adults above the age of 18 as part of India's inoculation drive.